Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference

Mar 02, 2011, 07:00 ET from Cempra Pharmaceuticals Inc.

CHAPEL HILL, N.C., March 2, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Cowen and Company 31st Annual Health Care Conference at 1:30 p.m. EST, March 7, 2011, at The Boston Marriott Copley Place in Boston.  Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and TAKSTATM for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com.

Media Contacts:

Robert E. Flamm, Ph.D.

Russo Partners, LLC

(212) 845-4226


Tony Russo, Ph.D.

Russo Partners, LLC

(212) 845-4251


SOURCE Cempra Pharmaceuticals Inc.